In fact, a higher expression level of EIF5A2 has been reported to be correlated with decreased doxorubicin sensitivity in breast cancer cell lines [32], and ablation of EIF5A2 enhanced chemosensitivity of HCC cells to 5-Fu [33]. Here, EIF5A2 is linked to breast carcinoma.